AbCellera
Healthcare & Life Sci
Company overview
AbCellera is a biotech company that develops antibody-based medicines using its own single-cell screening technology. ABCL635 is a first-in-class antibody in Phase 1/2 trials for the non-hormonal treatment of vasomotor symptoms. ABCL575 is a monoclonal antibody for atopic dermatitis that entered Phase 1 trials in the third quarter of 2025. The company is based in Vancouver, Canada.
AbCellera was founded in 2012. It is a public company, trading on the Nasdaq under the ticker ABCL, and employs about 596 people. That combination means outside investors see its pipeline results and spending decisions every quarter, a level of transparency most private biotechs don't have. Historically, the median salary is ~$107,750.
- Industry
- Healthcare & Life Sci
- Headquarters
- Vancouver, Canada